ThuJan 14th, 2021
Lantern Pharma Announces Pricing of $60 Million Public Offering
Lantern Pharma Announces Pricing of $60 Million Public Offering [...]
MonJan 4th, 2021
Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program through Agreement with Califia Pharma
Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) [...]
TueDec 15th, 2020
Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers
Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood [...]
MonOct 5th, 2020
Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent
Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with [...]
TueSep 22nd, 2020
Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer
Lantern Pharma Announces Collaboration and Research Agreement with Fox [...]
ThuAug 27th, 2020
Lantern Pharma Announces Upcoming Conference Presentations
Lantern Pharma Announces Upcoming Conference Presentations Aug 27, 2020, [...]